FREEMAN KEVIN D 4
4 · GALECTIN THERAPEUTICS INC · Filed Oct 16, 2024
Insider Transaction Report
Form 4
FREEMAN KEVIN D
Director
Transactions
- Purchase
Common Stock
2024-10-16$2.70/sh+5,000$13,500→ 80,000 total(indirect: By LLC) - Purchase
Common Stock
2024-10-16$2.70/sh+5,000$13,500→ 33,469 total
Holdings
- 18,063(indirect: By IRA)
Common Stock
Footnotes (1)
- [F1]Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.